Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with or without tremelimumab in pediatric relapsed or refractory advanced cancers
NL-OMON55864Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab and tremelimumab in Non-hematologic malignancy, hematopoietic malignancies, lymphoma and 1 more (2 arms), sponsored by AstraZeneca. Primary endpoints: Adult equivalent exposure and MTD/recommended pediatric dose, Safety and tolerability and 2 more. Started Mar 2019; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
Non-hematologic malignancyhematopoietic malignancieslymphomaAcute Leukaemia
Beyond the preview
Go deeper on NL-OMON55864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55864.